Vanin-1 inactivation antagonizes the development of adrenocortical neoplasia in Sf-1 transgenic mice

Endocrinology

Volumn 155, Issue 7, 2014, Pages 2349-2354

  De Late, Perle Latre ^a,b,c   El Wakil, Abeer ^a,b,c   Jarjat, Marielle ^a,b,c   De Krijger, Ronald R ^d   Heckert, Leslie L ^e   Naquet, Philippe ^f,g   Lalli, Enzo ^a,b,c  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b Assoc Intl Lab for the Study of the ALterations of Gene Expression in Childhood Cancers CNRS   (France)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^f CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^g INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTAMINE; PROTEIN; STEROIDOGENIC FACTOR 1; UNCLASSIFIED DRUG; VANIN 1;

ADRENAL CORTEX; ADRENAL CORTEX TUMOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; DETOXIFICATION; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ADRENAL CORTEX; ADRENAL CORTEX NEOPLASMS; AMIDOHYDROLASES; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYSTEAMINE; DISEASE PROGRESSION; FEMALE; GLUTATHIONE; GPI-LINKED PROTEINS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, BIOLOGICAL; REACTIVE OXYGEN SPECIES; STEROIDOGENIC FACTOR 1; TIME FACTORS;

EID: 84903288853     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1088     Document Type: Article

References (25)

1. Fassnacht, M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol. 2011;7:323-335.
2. Pianovski MA, Cavalli LR, Figueiredo BC, et al. SF-1 overexpression in childhood adrenocortical tumours. Eur J Cancer. 2006;42:1040-1043.
3. Sbiera S, Schmull S, Assie G, et al. High diagnostic and prognostic value of Steroidogenic Factor-1 expression in adrenal tumors. J Clin Endocrinol Metab. 2010;95:E161-E171.
4. Doghman M, Karpova T, Rodrigues GA, et al. Increased Steroidogenic Factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol Endocrinol. 2007;21:2968-2987. (Pubitemid 350223508)
5. Doghman M, Figueiredo BC, Volante M, Papotti M, Lalli E. Integrative analysis of SF-1 transcription factor dosage impact on genome-wide binding and gene expression regulation. Nucleic Acids Res. 2013;41:8896-8907.
6. Wilson MJ, Jeyasuria P, Parker KL, Koopman P. The transcription factors Steroidogenic Factor-1 and SOX9 regulate expression of Vanin-1 during mouse testis development. J Biol Chem. 2005;280:5917-5923. (Pubitemid 40280075)
7. Aurrand-Lions M, Galland F, Bazin H, Zakharyev VM, Imhof BA, Naquet P. Vanin-1, a novel GPI-linked perivascular molecule involved in thymus homing. Immunity. 1996;5:391-405. (Pubitemid 26423468)
8. Pitari G, Malergue F, Martin F, et al. Pantetheinase activity of membrane-bound Vanin-1: lack of free cysteamine in tissues of Vanin-1 deficient mice. FEBS Lett. 2000;483:149-154.
9. Berruyer C, Martin FM, Castellano R, et al. Vanin-1-/- mice exhibit a glutathione-mediated tissue resistance to oxidative stress. Mol Cell Biol. 2004;24:7214-7224. (Pubitemid 39014447)
10. Martin F, Penet MF, Malergue F, et al. Vanin-1(-/-) mice show decreased NSAID- and Schistosoma-induced intestinal inflammation associated with higher glutathione stores. J Clin Invest. 2004;113:591-597. (Pubitemid 38542508)
11. Berruyer C, Pouyet L, Millet V, et al. Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity. J Exp Med. 2006;203:2817-2827. (Pubitemid 46026160)
12. Roisin-Bouffay C, Castellano R, Valéro R, Chasson L, Galland F, Naquet P. Mouse vanin-1 is cytoprotective for islet beta cells and regulates the development of type 1 diabetes. Diabetologia. 2008;51:1192-1201.
13. Pouyet L, Roisin-Bouffay C, Clément A, et al. Epithelial vanin-1 controls inflammation-driven carcinogenesis in the colitis-associated colon cancer model. Inflamm Bowel Dis. 2010;16:96-104.
14. Karpova T, Presley J, Manimaran RR, et al. A Ftz-F1-containing yeast artificial chromosome recapitulates expression of steroidogenic factor 1 in vivo. Mol Endocrinol. 2005;19:2549-2563. (Pubitemid 41362668)
15. Rommelaere S, Millet V, Gensollen T, et al. PPARalpha regulates the production of serum Vanin-1 by liver. FEBS Lett. 2013;587:3742-3748.
16. Lalli E. Adrenocortical development and cancer: focus on SF-1. J Mol Endocrinol. 2010;44:301-307.
17. Bielinska M, Kiiveri S, Parviainen H, Mannisto S, Heikinheimo M, Wilson DB. Gonadectomy-induced adrenocortical neoplasia in the domestic ferret (Mustela putorius furo) and laboratory mouse. Vet Pathol. 2006;43:97-117.
18. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003;149:273-285. (Pubitemid 37304697)
19. Dunn TB. Normal and pathologic anatomy of the adrenal gland of the mouse, including neoplasms. J Natl Cancer Inst. 1970;44:1323-1389.
20. Goodman DG. Subcapsular-cell hyperplasia, adrenal mouse. In: Jones TC, Mohr U, Hunt R, eds. Monographs on Pathology of Laboratory Animals: Endocrine System. Berlin: Springer-Verlag; 1983:66-68.
21. Markello TC, Bernardini IM, Gahl WA. Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med. 1993;328:1157-1162. (Pubitemid 23105753)
22. Dammanahalli KJ, Stevens S, Terkeltaub R. Vanin-1 pantetheinase drives smooth muscle cell activation in post-arterial injury neointimal hyperplasia. PLoS One. 2013;7:e39106.
23. Lalli E, Doghman M, Latre de Late P, El Wakil A, Mus-Veteau I. Beyond steroidogenesis: novel target genes for SF-1 discovered by genomics. Mol Cell Endocrinol. 2013;371:154-159.
24. Matsumura T, Imamichi Y, Mizutani T, et al. Human glutathione S-transferase A (GSTA) family genes are regulated by steroidogenic factor 1 (SF-1) and are involved in steroidogenesis. FASEB J. 2013;27:3198-3208.
25. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12:931-947.